Gallic Acid
Research reviewed: Up until 03/2026
Gallic Acid is a dietary supplement with 9 published peer-reviewed studies involving 590 participants, researched for Antioxidant Activity, Blood Sugar Control, Cardiovascular Health and 1 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Antioxidant Activity
ModerateBlood Sugar Control
ModerateCardiovascular Health
ModerateAnti-cancer Activity
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Antioxidant Activity
To evaluate antioxidant effects of Gallic Acid supplementation in patients with type 2 diabetes
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To evaluate antioxidant effects of Gallic Acid supplementation in patients with type 2 diabetes
Dose
800 mg Gallic Acid daily
Participants
60 adults with type 2 diabetes
Duration
8 weeks
Results
Gallic Acid supplementation significantly reduced oxidative stress markers (TBARS −22%), enhanced antioxidant enzyme activities (SOD +18%, GPx +21%), and increased plasma total antioxidant capacity vs placebo.
How They Measured It
TBARS, SOD, catalase, GPx, plasma total antioxidant capacity
To characterize the free radical scavenging mechanisms and metal chelating capacity of Gallic Acid
Study Type
In vitro study
Purpose
To characterize the free radical scavenging mechanisms and metal chelating capacity of Gallic Acid
Dose
1-500 μM Gallic Acid
Participants
Biochemical assay systems
Duration
Various
Results
Gallic Acid demonstrated exceptionally potent antioxidant activity (DPPH IC50: 4.6 μM), effective superoxide and hydroxyl radical scavenging, and iron chelation, establishing it as one of the most potent plant-derived antioxidants.
How They Measured It
DPPH, ABTS, FRAP, superoxide and hydroxyl radical scavenging assays
Blood Sugar Control
To evaluate Gallic Acid supplementation on insulin resistance and glycemic control
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To evaluate Gallic Acid supplementation on insulin resistance and glycemic control
Dose
1000 mg Gallic Acid daily
Participants
90 adults with insulin resistance
Duration
12 weeks
Results
Gallic Acid significantly improved insulin sensitivity (HOMA-IR −19%), reduced fasting glucose (−8%), modestly reduced HbA1c, and improved adiponectin levels compared to placebo. No adverse events.
How They Measured It
HOMA-IR, fasting glucose, insulin, HbA1c, adipokines
To investigate mechanisms of Gallic Acid in regulating postprandial glucose in diabetic rats
Study Type
Animal study
Purpose
To investigate mechanisms of Gallic Acid in regulating postprandial glucose in diabetic rats
Dose
50-200 mg/kg Gallic Acid
Participants
24 STZ-induced diabetic rats
Duration
6 weeks
Results
Gallic Acid significantly inhibited intestinal α-glucosidase activity, reduced GLUT2 expression in the intestine, suppressed hepatic glucose output via AMPK activation, and improved overall glycemic control.
How They Measured It
α-glucosidase inhibition, GLUT2 expression, hepatic glucose output, AMPK activation
Cardiovascular Health
To evaluate Gallic Acid on lipid profiles and arterial stiffness in dyslipidaemic subjects
Study Type
Randomised controlled trial
Purpose
To evaluate Gallic Acid on lipid profiles and arterial stiffness in dyslipidaemic subjects
Dose
600 mg Gallic Acid daily
Participants
80 adults with dyslipidemia
Duration
10 weeks
Results
Gallic Acid supplementation significantly reduced total cholesterol (−11%), LDL (−14%), triglycerides, and arterial stiffness (baPWV), while increasing HDL. hs-CRP was also reduced significantly vs placebo.
How They Measured It
Lipid panel (TC, LDL, HDL, TG), PWV, brachial-ankle PWV, hs-CRP
To investigate the anti-platelet and anti-thrombotic mechanisms of Gallic Acid
Study Type
In vitro study
Purpose
To investigate the anti-platelet and anti-thrombotic mechanisms of Gallic Acid
Dose
1-100 μM Gallic Acid
Participants
Human platelet-rich plasma
Duration
2 hours
Results
Gallic Acid potently inhibited collagen and ADP-induced platelet aggregation, reduced thromboxane B2 production, suppressed P-selectin expression, and reduced fibrinogen binding to platelets.
How They Measured It
Platelet aggregation assay, thromboxane B2, P-selectin expression, fibrinogen binding
Anti-cancer Activity
To evaluate the anticancer mechanisms of Gallic Acid across multiple cancer cell types
Study Type
In vitro study
Purpose
To evaluate the anticancer mechanisms of Gallic Acid across multiple cancer cell types
Dose
10-100 μM Gallic Acid
Participants
MCF-7, HeLa, HCT116, PC-3 cancer cell lines
Duration
48 hours
Results
Gallic Acid induced selective cytotoxicity in cancer cells (IC50 15-45 μM) with minimal toxicity to normal cells. Mechanisms included ROS generation, mitochondrial membrane disruption, caspase activation, and p53 upregulation.
How They Measured It
Cell viability, apoptosis, ROS generation, mitochondrial pathway, p53 expression
To comprehensively review the anti-cancer properties and mechanisms of Gallic Acid
Study Type
Systematic review
Purpose
To comprehensively review the anti-cancer properties and mechanisms of Gallic Acid
Dose
Various concentrations
Participants
Review of 50+ pre-clinical studies
Duration
Various
Results
Gallic Acid demonstrates broad-spectrum anticancer activity against breast, colon, lung, prostate, and cervical cancers. Multiple mechanisms identified including pro-oxidant effects in cancer cells, apoptosis induction, and angiogenesis inhibition.
How They Measured It
Systematic review of in vitro and in vivo anti-cancer studies
To evaluate Gallic Acid as a chemopreventive agent in a colon cancer model
Study Type
Animal study
Purpose
To evaluate Gallic Acid as a chemopreventive agent in a colon cancer model
Dose
100-300 mg/kg Gallic Acid
Participants
24 rats with DMH-induced colon carcinogenesis
Duration
20 weeks
Results
Gallic Acid significantly reduced aberrant crypt foci formation, lowered tumor incidence, and induced phase II detoxification enzymes while reducing oxidative stress in the colon of carcinogen-exposed rats.
How They Measured It
ACF formation, tumor incidence, oxidative stress, phase II enzyme induction
Frequently Asked Questions
Common questions about Gallic Acid research
There are currently 9 peer-reviewed studies on Gallic Acid (Gallic Acid), involving 590 total participants. Research covers Antioxidant activity, Blood sugar control, Cardiovascular health and 1 more areas. The overall evidence strength is rated as Very Strong.
The evidence is currently rated as "Very Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (9 human studies), and reported outcomes.
Gallic Acid has been researched for: Antioxidant activity, Blood sugar control, Cardiovascular health, Anti-cancer activity. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 9 out of 9 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
